Physician profile
Dean Chang
NPI 1770564247
$16,434.22
in general payments reported to CMS, 2019-2025
37 companies · $4,070 in 2025
The $4,070 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,454 · 2020: $574 · 2021: $3,134 · 2022: $1,663 · 2023: $2,504 · 2024: $3,034 · 2025: $4,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,609.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,902.77 | 2019-2025 | Epclusa, Livdelzi, Vemlidy |
| Abbvie INC. | $3,694.49 | 2019-2025 | Creon, Linzess, Viberzi |
| Madrigal Pharmaceuticals | $805.27 | 2025 | Rezdiffra |
| Celgene Corporation | $794.78 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $714.89 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $703.96 | 2020-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $565.44 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $543.91 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $532.50 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Redhill Biopharma INC. | $358.26 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $322.27 | 2024-2025 | Zenpep |
| Pfizer INC. | $302.07 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $249.38 | 2019-2024 | Farxiga |
| Ironwood Pharmaceuticals, INC | $240.20 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $207.83 | 2021-2025 | Ocaliva |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $200.71 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $168.80 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $165.36 | 2023-2025 | Dupixent |
| Genzyme Corporation | $146.56 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $143.92 | 2019-2024 | Rebyota |
| Lilly USA, LLC | $128.32 | 2024-2025 | Omvoh, Zepbound |
| Allergan, INC. | $80.55 | 2019 | |
| Pentax of America, INC. | $64.55 | 2021-2023 | Pentax Medical |
| Ipsen Biopharmaceuticals, INC | $63.78 | 2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $63.38 | 2023-2024 | Idacio |
| Shionogi INC | $46.87 | 2019 | |
| Braintree Laboratories, INC. | $33.78 | 2025 | Suflave, Sutab |
| Boston Scientific Corporation | $28.96 | 2022 | |
| Mirum Pharmaceuticals, INC. | $23.04 | 2025 | Livmarli, Chenodal, Cholbam |
| Nestle Healthcare Nutrition INC. | $22.94 | 2023 | |
| Digestive Care, INC. | $21.75 | 2025 | Pertzye |
| Intra-Sana Laboratories | $20.17 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Vivus LLC | $17.10 | 2025 | Pancreaze |
| Tempus Ai, INC | $16.39 | 2024 | Xt Cdx |
| Merck Sharp & Dohme LLC | $13.99 | 2024 | Dificid |
| Portola Pharmaceuticals, LLC | $13.20 | 2019 | |
| Olympus America INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.